ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
暂无分享,去创建一个
Eunhee Kim | Claude Preudhomme | Alessandro Pastore | Omar Abdel-Wahab | Young Rock Chung | Daichi Inoue | Richard Koche | Andrei Krivtsov | O. Abdel-Wahab | E. Solary | R. Koche | C. Preudhomme | A. Sinha | A. Pastore | A. Krivtsov | Hana Cho | Eunhee Kim | Y. R. Chung | D. Inoue | A. Yoshimi | J. Micol | Eric Solary | Jean-Baptiste Micol | B. Durham | Akihide Yoshimi | Nicolas Duployez | Stanley Chun-Wei Lee | Benjamin H Durham | Hana Cho | Xiao Jing Zhang | Amit Sinha | X. J. Zhang | N. Duployez | Stanley C. Lee
[1] Salam A. Assi,et al. Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-Renewal , 2014, Cell reports.
[2] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[3] O. Elemento,et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development , 2015, Nature Medicine.
[4] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[5] Somasekar Seshagiri,et al. Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation , 2012, Science.
[6] Heather L. Mulder,et al. The genomic landscape of core-binding factor acute myeloid leukemias , 2016, Nature Genetics.
[7] K. Mills,et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia , 2007, Leukemia.
[8] C. Bach,et al. Leukemogenic transformation by HOXA cluster genes. , 2010, Blood.
[9] Xiaobo Xia,et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.
[10] K. Akashi,et al. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell. , 2014, Experimental hematology.
[11] C. Glass,et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.
[12] W. Alexander,et al. Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis. , 2015, Blood.
[13] Scott A. Armstrong,et al. MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.
[14] D. Birnbaum,et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Young,et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state , 2010, Proceedings of the National Academy of Sciences.
[16] J. Hess,et al. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. , 2010, Blood.
[17] B. Porse,et al. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis , 2015, Genes & development.
[18] M. Katoh,et al. Identification and characterization of ASXL2 gene in silico. , 2003, International journal of oncology.
[19] Bob Löwenberg,et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value , 2012, Haematologica.
[20] S. Orkin,et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. , 2014, Cell stem cell.
[21] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[22] H. Stunnenberg,et al. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. , 2012, Blood.
[23] K. Akashi,et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. , 1996, Blood.
[24] S. González,et al. Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. , 2012, Cell stem cell.
[25] V. Vacic,et al. Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles , 2016, The Journal of experimental medicine.
[26] S. Armstrong,et al. Loss of BAP1 function leads to EZH2-dependent transformation , 2015, Nature Medicine.
[27] T. Milne,et al. The Additional sex combs gene of Drosophila is required for activation and repression of homeotic loci, and interacts specifically with Polycomb and super sex combs , 1999, Molecular and General Genetics MGG.
[28] C. Mason,et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo , 2013, The Journal of experimental medicine.
[29] U. Thorsteinsdóttir,et al. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia , 1997, Molecular and cellular biology.
[30] R. Fulton,et al. Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells , 2015, Leukemia.
[31] O. Abdel-Wahab,et al. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. , 2014, Blood.
[32] O. Abdel-Wahab,et al. A novel tumor suppressor function for the Notch pathway in myeloid leukemia , 2011, Nature.
[33] R. Humphries,et al. Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family. , 2006, Gene.
[34] Heather L. Mulder,et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes , 2014, Nature Communications.
[35] E. Zeggini,et al. Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis , 2015, Cell reports.
[36] S. Morrison,et al. SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. , 2013, Cell stem cell.
[37] S. Korsmeyer,et al. Definitive hematopoiesis requires the mixed-lineage leukemia gene. , 2004, Developmental cell.
[38] A. Iwama,et al. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner. , 2015, Blood.
[39] K. Helin,et al. Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation , 2013, Nature Cell Biology.
[40] C. Schumann,et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Unnur Thorsteinsdottir,et al. Defining Roles for HOX and MEIS1 Genes in Induction of Acute Myeloid Leukemia , 2001, Molecular and Cellular Biology.
[42] Salam A. Assi,et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding , 2012, Leukemia.
[43] Q. T. Wang,et al. Functional Conservation of Asxl2, a Murine Homolog for the Drosophila Enhancer of Trithorax and Polycomb Group Gene Asx , 2009, PloS one.
[44] Iannis Aifantis,et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.
[45] J. Cigudosa,et al. Chromatin Modifications Induced by the AML1/ETO Fusion Protein Reversibly Silence Its Genomic Targets Through AML1 and Sp1 Binding Motifs , 2011 .
[46] O. Abdel-Wahab,et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. , 2016, Blood.
[47] M. Kyba,et al. The Additional sex combs gene of Drosophila encodes a chromatin protein that binds to shared and unique Polycomb group sites on polytene chromosomes. , 1998, Development.
[48] Yi Ning,et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.
[49] K. Basso,et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis , 2015, Nature Medicine.
[50] D. Catovsky,et al. Disease Features in Acute Myeloid Leukemia with t(8;21)(q22;q22). Influence of Age, Secondary Karyotype Abnormalities, CD19 Status, and Extramedullar Leukemia on Survival , 2000, Leukemia & lymphoma.
[51] P. Farnham,et al. Using ChIP-seq technology to generate high-resolution profiles of histone modifications. , 2011, Methods in molecular biology.
[52] Zhu Chen,et al. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia. , 2016, Blood.
[53] J. Cigudosa,et al. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs , 2012, Leukemia.
[54] S. Yoon,et al. Additional Sex Comb-like (ASXL) Proteins 1 and 2 Play Opposite Roles in Adipogenesis via Reciprocal Regulation of Peroxisome Proliferator-activated Receptor γ* , 2010, The Journal of Biological Chemistry.
[55] Salam A. Assi,et al. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. , 2016, Cancer cell.
[56] Daniel Birnbaum,et al. Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.
[57] Zhaomin Li,et al. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. , 2014, Blood.
[58] Clifford A. Meyer,et al. Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.
[59] Howard Y. Chang,et al. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position , 2013, Nature Methods.
[60] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[61] H. Lähdesmäki,et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex , 2015, Nature Communications.
[62] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[63] J. Downing,et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.
[64] Ming Yan,et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis , 2006, Nature Medicine.
[65] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[66] Ryan A. Flynn,et al. A unique chromatin signature uncovers early developmental enhancers in humans , 2011, Nature.
[67] Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes , 2013 .
[68] W. Hur,et al. ASXL2 promotes proliferation of breast cancer cells by linking ERα to histone methylation , 2016, Oncogene.
[69] Nathaniel D. Heintzman,et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome , 2007, Nature Genetics.
[70] I. Weissman,et al. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.